CTNM – contineum therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain [Yahoo! Finance]
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $31.00. They now have an "outperform" rating on the stock.
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Form 4 Contineum Therapeutics, For: Nov 18 Filed by: Lorrain Daniel S.
Form 144 Contineum Therapeutics, Filed by: Lorrain Daniel S.
Form SC 13G Contineum Therapeutics, Filed by: SECTORAL ASSET MANAGEMENT INC
Form 10-Q Contineum Therapeutics, For: Sep 30
Form 8-K Contineum Therapeutics, For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.